Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
  • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
  • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/08—Drugs for disorders of the urinary system of the prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
  • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
  • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
  • C07K5/06008—Dipeptides with the first amino acid being neutral
  • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
  • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0802—Tripeptides with the first amino acid being neutral
  • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
  • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0819—Tripeptides with the first amino acid being acidic
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to the synthesis of novel charged cross linkers and cross linkers which can be processed by a target cell to give charged moieties.
• the present invention also relates to methods of making cell-binding agent-drug conjugates comprising modification of cell-binding agents with these cross-linkers, followed by reaction with drugs, or modification of the drugs with these crosslinkers, followed by reaction with cell-binding agents.
• the improved method of making conjugates provides the ability to link a higher number of drug molecules per cell-binding agent resulting in greater potency and providing greater aqueous solubility to the conjugates.
• the bifunctional modification reagent iV-succinimidyl 3-(2- pyridyldithio) propionate (SPDP) has been used to link two proteins together through a disulfide bond.
• the reagent is reacted with the first protein to introduce an active disulfide-containing group in the modification step.
• a second protein, which contains a free thiol group, is then added to form a disulfide bond between the two proteins in the conjugation step.
• Many derivatives of SPDP and imide versions of SPDP have been described (U.S. Patent 4,563,304; J. Carlsson et al. 173 Biochem. J. 723-737 (1978); Goff D. A., Carroll, S. F.
• Conjugates of cell-binding agents with highly cytotoxic drugs have been described (U.S. Patent Nos. 5,208,020, 5,416,064; 5,475,092, 5,585,499, 6,436,931, 6,372,738 and 6,340,701; R.V.J. Chari et al., 52 Cancer Res. 127-131 (1992)).
• the cell-binding agents are first modified with a bifunctional agent such as SPDP, SPP or SMCC to introduce an active disulfide or a maleimido moiety.
• Reaction with a thiol-containing cytotoxic drug provides a conjugate in which the cell-binding agent, such as a monoclonal antibody, and drug are linked via disulfide bonds or thioether bonds.
• Heterobifunctional cross-linkers comprising a nitropyridyldithio, dinitropyridyldithio, N. iV-dialkylcarboxamidopyridyldithio or di-(iV.iV-dialkylcarboxamido) pyridyldithio group and a reactive carboxylic ester group such as a iV-succinimidyl ester group or a iV-sulfosuccinimidyl ester group have been described (U.S. Patent No. 6,913,748).
• the present invention provides charged linkers, wherein the charges are retained both after modification of the cell-binding agent and in the resulting drug conjugate. More specifically, the present invention relates to the use of charged linkers to link drugs to a cell-binding agent (e.g., an antibody). In one aspect of the invention, the charged linkers are used to modify cell-binding agents and link them to drugs. In another aspect of the invention, the charged linkers are used to modify drugs and link them to cell- binding agents. In yet another aspect of the invention, the charged linkers are used to simultaneously link drugs and the cell-binding agents.
• a cell-binding agent e.g., an antibody
• the preferred end result is a drug-charged linker-cell-binding agent conjugate, which can be represented by the formula, CB-(-L c -D) q , wherein CB is a cell- binding agent, L c is a charged linker, D is a drug molecule, and q is an integer from 1 to 20.
• a charged group(s) in the linker in the cell- binding agent-drag conjugate provides several advantages, such as i) greater water solubility of the final product, ii) ability to operate at a higher concentration in aqueous solutions, iii) ability to link a greater number of drug molecules per molecule of cell-binding agent, resulting in higher potency, iv) potential for the charged conjugate species to be retained inside the target cell, resulting in higher potency, and v) improved sensitivity of multidrug resistant cells, which would be unable to export the charged drug species from the cell.
• the invention also describes linkers, which can be coupled to a drug and a cell binding agent to give a conjugate which can be metabolized in a cell to produce a drag metabolite containing one or more charged moieties.
• linkers will be referred to as pro-charged linkers.
• Moieties of the linker which will become charged after cell processing will be referred to as pro-charged moieties.
• the charged or pro- charged cross linker is represented by formula (I) wherein Y' can react with a cell-binding agent and Q can react with a cytotoxic drug:
• Q represents a functional group that enables linkage of a cytotoxic drug via a disulfide, thioether, thioester, peptide, hydrazone, ether, ester, carbamate or amide bond;
• R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are the same or different and are H, linear alkyl having from 1-6 carbon atoms, branched or cyclic alkyl having from 3 to 6 carbon atoms, linear, branched or cyclic alkenyl or alkynyl having from 2 to 6 carbon atoms, anions, such as but not limited to, SO 3 " , X-SO 3 " , OPO 3 2" , X-OPO 3 2" , PO 3 2" , X-PO 3 2” , CO 2 " , and cations, such as but not limited to, a nitrogen containing heterocycle, N + R 11 R 12 R 13 or X-N + R 11 R 12 Ri 3 , or a phenyl, wherein:
• Rn, Rj 2 and Rj 3 are the same or different and are H, linear alkyl having from 1 to 6 carbon atoms, or branched or cyclic alkyl having from 3 to 6 carbon atoms and X represents phenyl or a linear alkyl having from 1 to 6 carbon atoms, or a branched or cyclic alkyl having from 3 to 6 carbon atoms;
• n are O or an integer from 1 to 4.
• A is a phenyl or a substituted phenyl, wherein the substituent is a linear alkyl having from 1 to 6 carbon atoms, or a branched or cyclic alkyl having from 3 to 6 carbon atoms, or a charged substituent selected from anions, such as but not limited to, SO 3 " , X-SO 3 " , OPO 3 2" , X-OPO 3 2" , PO 3 2" , X- PO 3 2” , CO 2 " , and cations, such as but not limited to, a nitrogen containing heterocycle, N + R 11 Ri 2 Ri 3 or X-N + RnRi 2 R 13 , wherein X has the same definition as above, and wherein g is 0 or 1 ;
• the present invention provides a cell-binding agent-drug conjugate of formula (II), in which the cell-binding agent, CB, and the drug, D, have reacted at the two ends of the charged or pro-charged cross linker:
• CB represents a cell-binding agent
• D represents the drug linked to the cell-binding agent by a disulfide, thioether, thioester, peptide, hydrazone, ether, ester, carbamate, or amide bond;
• R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are the same or different and are H, linear alkyl having from 1-6 carbon atoms, branched or cyclic alkyl having from 3 to 6 carbon atoms, linear, branched or cyclic alkenyl or alkynyl having from 2 to 6 carbon atoms, anions, such as but not limited to, SO 3 " . X- SO 3 " .
• R 11 , R 12 and Rj 3 are the same or different and are H, linear alkyl having from 1 to 6 carbon atoms, branched or cyclic alkyl having from 3 to 6 carbon atoms and X represents phenyl or a linear alkyl having from 1 to 6 carbon atoms, or a branched or cyclic alkyl having from 3 to 6 carbon atoms; 1, m and n are 0 or an integer from 1 to 4; and A is a phenyl or substituted phenyl, wherein the substituent is a linear alkyl having from 1 to 6 carbon atoms, or a branched or cyclic alkyl having from 3 to 6 carbon atoms, or a charged substituent selected from anions, such as but not limited to, SO 3 " .
• the present invention provides a modified cell-binding agent of formula (III), in which the cell-binding agent, CB, has reacted with the cross linker, which still has Q, a group capable of reacting with a cytotoxic drug:
• the present invention provides a modified drug of formula (IV), in which the drug, D, has reacted with the cross linker, which still has Y', a group capable of reacting with the cell- binding agent:
• the present invention further relates to a method of making a cell-binding agent drug conjugate of formula (II), wherein the drug is linked to a cell-binding agent via a charged or pro-charged linker.
• the present invention also relates to a method of making a modified cell-binding agent of formula (III), wherein the cell-binding agent is reacted with the charged or pro-charged linker.
• the present invention also relates to a method of making a modified drug of formula (IV), wherein the drug is reacted with the charged or pro-charged linker.
• the present invention includes a composition (e.g., a pharmaceutical composition) comprising conjugates or derivatives thereof (and/or solvates, hydrates and/or salts thereof) and a carrier (a pharmaceutically acceptable carrier).
• a composition e.g., a pharmaceutical composition
• the present invention also includes a composition (e.g., a pharmaceutical composition) comprising conjugates or derivatives thereof, (and/or solvates, hydrates and/or salts thereof) and a carrier (a pharmaceutically acceptable carrier), further comprising a second therapeutic agent.
• the present compositions are useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal (e.g., human).
• the present invention includes a method of inhibiting abnormal cell growth or treating a proliferative disorder in a mammal (e.g., human) comprising administering to said mammal a therapeutically effective amount of the conjugates or derivatives thereof, (and/or solvates and salts thereof) or a composition thereof, alone or in combination with a second therapeutic agent.
• a mammal e.g., human
• the compounds of this invention, derivatives thereof, or conjugates thereof, and compositions comprising them are useful for treating or lessening the severity of disorders, such as, characterized by abnormal growth of cells (e.g., cancer).
• compositions or conjugates of this invention include, but are not limited to, treating osteoporosis, depression, anxiety, stress, phobias, panic, dysphoria, psychiatric disorders, and pain or as antiepileptics, antibacterials, diuretics and hypotensives, hypolipidemics, and anti-depressants.
• Figure 1 shows the synthesis of sulfonic acid-containing cross- linking reagents that contain a nitropyridyldisulfide group and a reactive carboxylic acid ester. Hydroxyalkanoate esters are first converted into dibromoalkanoate esters as shown, followed by conversion of the ⁇ -bromo substituent into a sulfonic acid.
• Figure 2 shows the synthesis of sulfonic acid-containing cross- linking reagents that contain a pyridyldisulf ⁇ de group and a reactive carboxylic acid ester.
• Figures 3, 4 and 5 show various routes for the synthesis of charged cross-linking agents bearing a reactive carboxylic acid ester and maleimido substituent, enabling linkage via thioether bonds.
• Figures 6 and 7 show the synthesis of phosphate-containing cross-linking reagents that contain a pyridyldisulfide group and a reactive carboxylic acid ester.
• Figure 8 shows the synthesis of phosphate-containing cross- linking reagents that contain a nitropyridyldisulfide group and a reactive carboxylic acid ester
• Figures 9 and 10 show different routes for the synthesis of phosphate-containing charged cross-linking agents bearing a reactive carboxylic acid ester and a maleimido substituent, enabling linkage via thioether bonds.
• Figure 11 shows the synthesis of sulfonic acid-containing cross-linking reagents, where the sulfonate substituent is attached to a branched alkyl group. These reagents also bear a pyridyldisulfide group and a reactive carboxylic acid ester.
• Figure 12 shows the synthesis of sulfonic acid-containing cross-linking reagents, where the sulfonate substituent is attached to a branched alkyl group. These reagents also bear a reactive carboxylic acid ester and a maleimido group that allows for linkage via thioether bonds.
• Figure 13 shows the synthesis of quartenary amine-containing cross-linking reagents that contain a pyridyldisulfide group and a reactive carboxylic acid ester.
• Figure 14 shows the synthesis of quartenary amine cross- linking agents bearing a reactive carboxylic acid ester and maleimido substituent, enabling linkage via thioether bonds.
• Figure 15 shows the synthesis of sulfonic acid-containing cross-linking reagents that contain a pyridyldisulfide group and a reactive carboxylic acid ester. In these compounds, the sulfonate substituent is on the carbon atom on the position ⁇ to the carboxyl ester.
• Figure 16 shows the synthesis of phosphate-containing cross- linking reagents that contain a pyridyldisulfide group and a reactive carboxylic acid ester.
• the phosphate substituent is on the ⁇ -position relative to the carboxyl ester.
• Figures 17, 18 and 19 show the synthesis of various sulfonic acid-containing cross-linking reagents that contain a polyethyleneglycol (PEG) chain, along with a nitropyridyldisulfide group and a reactive carboxylic acid ester.
• Figures 20 and 21 show the synthesis of various sulfonic acid- containing cross-linking reagents that contain a polyethyleneglycol (PEG) chain, along with a maleimido group and a reactive carboxylic acid ester.
• Figure 22 shows the synthesis of phosphate-containing cross- linking reagents, where the phosphate substituent is attached to an aromatic group.
• FIG. 23 shows the synthesis of phosphate-containing cross- linking reagents, where the phosphate substituent is attached to a branched alkyl group. These reagents also bear a reactive carboxylic acid ester and a nitropyridyldithio group that allows for linkage via disulfide bonds.
• Figures 24 - 31 show the synthesis of sulfonate-containing cross-linking reagents that also incorporate a hydrazide moiety allowing for linkage via acid-labile bonds.
• Figures 32 - 36 show the synthesis of phosphate-containing cross-linking reagents that also incorporate a hydrazide moiety allowing for linkage via acid-labile bonds.
• Figures 37 - 38 show the synthesis of quartenary amine- containing cross-linking reagents that also incorporate a hydrazide moiety allowing for linkage via acid-labile bonds.
• Figures 39 - 42 show the synthesis of charged cross-linking reagents that also incorporate a polyethyleneglycol (PEG) moiety.
• Figures 43-44 show the synthesis of phosphate-containing cross-linking reagents, where the phosphate substituent is attached to an aromatic residue or to an alkyl group. These reagents also bear a reactive carboxylic acid ester and a nitropyridyldithio group that allows for linkage via disulfide bonds.
• Figures 45-49 show the synthesis of charged cross-linking agents bearing reactive carboxylic acid ester and a haloacetyl substituent, enabling linkage via thioether bonds.
• Figure 50 shows the synthesis of a procharged linker that would generate a negatively charged carboxylate metabolite.
• Figure 51 shows a conjugate of linker 158 to a drug and a monoclonal antibody and how the conjugate would be processed in the lysosome of a target cell to give a metabolite containing the drug bearing a negatively charged carboxylate.
• Figure 52 shows the synthesis of a procharged linker that would generate a positively charged amine-containing metabolite.
• Figure 53 shows a conjugate of a procharged linker to a drug and a monoclonal antibody and how the conjugate would be processed in the lysosome of a target cell to give a metabolite of the drug bearing a positively charged amine.
• Figure 54 shows the synthesis of a procharged linker that would generate a charged carboxylate metabolite.
• Figure 55 shows a conjugate of linker 172 to a drug and a moloclonal antibody and how the conjugate would be processed in the lysosome of a target cell to give a metabolite containing the drug bearing a carboxylic acid and a lysine residue.
• Figure 56 shows the use of charged linker in modifying a cell- binding agent and producing a cell-binding agent-drug conjugate bearing a charged linker.
• Figures 57(A), (B) and (C) show the in vitro potency of cell- binding agent-drug conjugates in which a charged crosslinker is incorporated.
• Figure 58 shows the in vitro potency and target selectivity of cell-binding agent-drug conjugates bearing a charged crosslinker.
• Figure 59 shows the mass spectrum of cell-binding agent-drug conjugates bearing a charged crosslinker.
• Figure 60 shows the cytotoxicity of Anti-CanAg (huC242) - sulfonate linker-maytansinoid conjugates with increasing maytansinoids load (E:A) toward COLO205 cells.
• Figure 61 shows the cytotoxicity of Anti-CanAg (huC242) - sulfonate linker-maytansinoid conjugates with increasing maytansinoids load (E: A) toward multi-drug resistant COLO205-MDR cells.
• Figure 62 compares cytotoxicity of Anti-CanAg (huC242) - maytansinoid conjugates with or without sulfonate group in the linker toward multi-drug resistant COLO205-MDR cells.
• Figure 63 compares the cytotoxicity of Anti-EpCAM (B38.1) - maytansinoid conjugates with or without sulfonate group in linker toward multi-drug resistant COLO205-MDR cells.
• Figure 64 compares the cytotoxicity of Anti-EpCAM (B38.1)- maytansinoid conjugates with or without sulfonate group in linker toward multi-drug resistant HCTl 5 cells.
• Figure 65 compares the cytotoxicity of Anti-EpCAM (B38.1) - maytansinoid conjugates with or without sulfonate group in linker toward multi-drug resistant COLO205-MDR cells.
• Figure 66 shows the in vivo anti-tumor activity of anti-EpCAM antibody-maytansinoid conjugates on COLO205 mdr xenografts (individual tumors).
• Figure 67 shows the in vivo anti-tumor activity of anti-EpCAM antibody-maytansinoid conjugates on COLO205 xenografts (individual tumors).
• Figures 68 - 70 show the methods of synthesis of sulfonic acid- containing cross-linking reagents. These reagents bear a reactive carboxylic acid ester and a maleimido group that allows for linkage via thioether bonds.
• Figure 71 shows the methods of synthesis of quartenary amine - containing cross-linking reagents. These reagents also bear a reactive carboxylic acid ester and a pyridyldithio group that allows for linkage via disulfide bonds.
• Figures 72(A) and (B) show Plasma pharmacokinetics of huC242 Antibody-Sulfo-Mal-[ 3 H-labeled]-DM4 conjugates with 3.5 DM4/Ab or 6.4 DM4/Ab dosed at 12.9 mg/kg and 7.9 mg/kg (i.v.) respectively in CD-I mice.
• B. Maytansinoid (DM4)/ Antibody (Ab) ratio versus time after administration.
• m represents 0 or an integer from 1 to 2000.
• the novel conjugates disclosed herein use charged or pro- charged cross-linkers. Examples of some suitable cross-linkers and their synthesis are shown in Figures 1 to 10.
• the charged or pro-charged cross-linkers are those containing sulfonate, phosphate, carboxyl or quaternary amine substituents that significantly increase the solubility of the modified cell-binding agent and the cell-binding agent-drug conjugates, especially for monoclonal antibody-drug conjugates with 2 to 20 drugs/antibody linked.
• Conjugates prepared from linkers containing a pro-charged moiety would produce one or more charged moieties after the conjugate is metabolized in a cell.
• FIG. 1 The synthetic routes to produce charged crosslinkers of the present invention are shown in Figures 1-49.
• Synthetic routes to produce linkers with pro-charged moieties are shown in figures 50, 52, and 54.
• Figures 51, 53 and 55 show a conjugate of each of the respective pro-charged linkers with a drug and a monoclonal antibody and how these conjugates would be metabolized in a target cell to give charged metabolites.
• the crosslinkers possess three elements: a) a substituent that is either charged or will become charged when conjugates employing these linkers are metabolized in cells.
• the charge will be either anionic, such as but not limited to, carboxylate, sulfonate or phosphate, or cationic, such as but not limited to, a tertiary, quaternary, or primary amine or a nitrogen-containing heterocycle, b) a group, such as a N-hydroxysuccimimide ester, maleimido group, haloacetyl group, and hydrazide, capable of reaction with a cell-binding agent, and c) a group, such as but not limited to, a disulfide, maleimide, haloacetyl, and hydrazide, capable of reaction with a drug.
• the charged or pro-charged substituent can be introduced by methods described herein.
• a sulfonate charge can be introduced by first treating a commercially available haloester compound with thioacetate to produce a thioacetyl compound, followed by oxidation of the thioacetyl group, using hydrogen peroxide, to a sulfonate group.
• Phosphate containing crosslinkers can be synthesized by methods described herein.
• a positively charged quaternary amine substituent can be introduced in the crosslinker by reaction of an amine with an ⁇ , ⁇ -unsaturated ketone (see, for example, Figures 13 and 37).
• a charged amine substituent can be introduced by displacement of a halogen with the amine or nitrogen containing heterocycle of choice.
• the cross-linkers are compounds of the formula (I) below:
• Q represents a functional group that enables linkage of a drug via a disulfide, thioether , thioester, peptide, hydrazone, ester, ether, carbamate or amide bond;
• R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R7, Rs 5 R ⁇ > > and R 10 are the same or different and are H, linear alkyl having from 1-6 carbon atoms, branched or cyclic alkyl having from 3 to 6 carbon atoms, linear, branched or cyclic alkenyl or alkynyl having from 2 to 6 carbon atoms, anions, such as but not limited to, SO 3 ; X-SO 3 " , OPO 3 2" , X-OPO 3 2" , PO 3 2" , X-PO 3 2” , CO 2 -, cations, such as but not limited to, a nitrogen containing heterocycle, N + R 11 R 12 R 13 or
• Rn, R 12 and R 13 are the same or different and are H, linear alkyl having from 1 to 6 carbon atoms, or branched or cyclic alkyl having from 3 to 6 carbon atoms and X represents phenyl or a linear alkyl having from 1 to 6 carbon atoms, or a branched or cyclic alkyl having from 3 to 6 carbon atoms;
• n are O or an integer from 1 to 4;
• A is a phenyl or substituted phenyl, wherein the substituent is a linear alkyl having from 1 to 6 carbon atoms, or a branched or cyclic alkyl having from 3 to 6 carbon atoms, or a charged substituent selected from anions, such as but not limited to, SO 3 " . X-SO 3 " .
• Examples of the functional group, Y', that enables reaction with a cell-binding agent include amine reacting agents such as but not limited to N-hydroxysuccinmide esters, p-nitrophenyl esters, dinitrophenyl esters, pentafluorophenyl esters; thiol reactive agents such as but not limited to pyridyldisulfides, nitropyridyldisulfides, maleimides, haloacetates and carboxylic acid chlorides.
• amine reacting agents such as but not limited to N-hydroxysuccinmide esters, p-nitrophenyl esters, dinitrophenyl esters, pentafluorophenyl esters
• thiol reactive agents such as but not limited to pyridyldisulfides, nitropyridyldisulfides, maleimides, haloacetates and carboxylic acid chlorides.
• Examples of the functional group, Q which enables linkage of a cytotoxic drug, include groups that enable linkage via a disulfide, thioether, thioester, peptide, hydrazone, ester, carbamate, or amide bond.
• Such functional groups include, but are not limited to, thiol, disulfide, amino, carboxy, aldehydes, maleimido, haloacetyl, hydrazines, and hydroxy.
• linear alkyls include methyl, ethyl, propyl, butyl, pentyl and hexyl.
• branched or cyclic alkyls having 3 to 6 carbon atoms include isopropyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
• Examples of linear alkenyls having 2 to 6 carbon atoms include ethenyl, propenyl, butenyl, pentenyl, hexenyl.
• Examples of branched or cyclic alkenyls having 2 to 6 carbon atoms include isobutenyl, isopentenyl,
• Examples of linear alkynyls having 2 to 6 carbon atoms include ethynyl, propynyl, butynyl, pentynyl, hexynyl.
• Examples of branched or cyclic alkynyls having up to 6 carbon atoms include 3 -methyl- 1 -butynyl, 3- methyl- 1 -penynyl, 4-methyl-2-hexynyl.
• Figure 57 exemplifies that cell-binding agent-drug conjugates prepared using a charged crosslinker of the present invention display high potency.
• the potency is target selective (see, for example, Figure 58), since, even after linkage of a high number of drug molecules, the conjugate is highly potent towards target cells, but much less potent towards non-target cells.
• mass spectral analysis demonstrates that the drugs are linked covalently to the cell-binding agent via the charged crosslinker.
• the conjugates of the present invention can be represented by the following formula, CB-(-L c -D) q , wherein CB is a cell-binding agent, L c is a charged or pro-charged linker, D is a drug molecule, and q is an integer from 1 to 20.
• the conjugates have the following formula (II):
• D represents a drug linked to the cell-binding agent by a disulfide, thioether, thioester, peptide, hydrazone, ester, carbamate or amide bond;
• Ri, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are the same or different and are H, linear alkyl having from 1-6 carbon atoms, branched or cyclic alkyl having from 3 to 6 carbon atoms, linear, branched or cyclic alkenyl or alkynyl having from 2 to 6 carbon atoms, anions, such as but not limited to, SO 3 " . X-SO 3 ' .
• Rn, Rj 2 and Ri 3 are same or different and are H, linear alkyl having from 1 to 6 carbon atoms, branched or cyclic alkyl having from 3 to 6 carbon atoms and X represents phenyl or a linear alkyl having from 1 to 6 carbon atoms, or a branched or cyclic alkyl having from 3 to 6 carbon atoms;
• n are O or an integer from 1 to 4;
• A is a phenyl or substituted phenyl, wherein the substituent is a linear alkyl having from 1 to 6 carbon atoms, or a branched or cyclic alkyl having from 3 to 6 carbon atoms, or a charged substituent selected from anions, such as but not limited to, SO 3 " . X-SO 3 " .
• Y represents a carbonyl, thioether, amide, disulfide, or hydrazone group; and q is an integer from 1 to 20.
• the drug can be any of many small molecule drugs, including, but not limited to, maytansinoids, CC- 1065 analogs, morpholinos, doxorubicins, taxanes, cryptophycins, epothilones, calicheamicins, auristatins, and pyrrolobenzodiazepine dimers.
• Z is an F1-E1-P-E2-F2 unit,
• the number of drugs bound to each cell-binding agent is 1-20, more preferably 2-18, and even more preferably 2-16, and most preferably 2-10.
• the cell-binding agent can be modified with the crosslinkers of the present invention to introduce reactive disulfide groups, maleimido, haloacetyl or hydrazide groups.
• Synthesis of the cell-binding agent-drug conjugates linked via disulfide bonds is achieved by a disulfide exchange between the disulfide bond in the modified cell-binding agent and a drug containing a free thiol group.
• Synthesis of the cell-binding agent-drug conjugates linked via thioether is achieved by reaction of the maleimido or haloacetyl modified cell-binding agent and a drug containing a free thiol group.
• Synthesis of conjugates bearing an acid labile hydrazone link can be achieved by reaction of a carbonyl group with the hydrazide moiety in the linker, by methods known in the art (see, for example, P. Hamann et al., BioConjugate Chem., 13; 40-46, 2002; B. Laguzza et al., J.Med. Chem., 32; 548-555, 1959; P. Trail et al., Cancer Res., 57; 100-105, 1997).
• the drug can be modified with the crosslinkers of the present invention to give a modified drug of formula (IV) bearing a functionality capable of reacting with a cell binding agent.
• a thiol-containing drug can be reacted with the charged or pro-charged crosslinker of formula (I) bearing a maleimdo substituent at neutral pH in aqueous buffer to give a drug connected to the charged linker via a thioether link.
• a thiol-containg drug can undergo disulfide exchange with a charged linker bearing a pyrdiyldithio moiety to give a modified drug attached via a disulfide bond to the charged crosslinker.
• a drug bearing a hydroxyl group can be reacted with a charged or pro-charged crosslinker bearing a halogen, in the presence of a mild base, to give a modified drug bearing an ether link.
• a hydroxyl group containing drug can be condensed with a charged crosslinker of formula (I) bearing a carboxyl group, in the presence of a dehydrating agent, such as dicyclohexylcarbodimide, to give an ester link.
• a dehydrating agent such as dicyclohexylcarbodimide
• An amino group containing drug can similarly undergo condensation with a carboxyl group on the charged or pro-charged crosslinker of formula (I) to give an amide bond.
• the conjugate may be purified by standard biochemical means, such as gel filtration on a Sephadex G25 or Sephacryl S300 column, adsorption chromatography, and ion exchange or by dialysis as previously described.
• the cell-binding agent-drug conjugates can be purified by chromatography such as by HPLC, medium pressure column chromatography or ion exchange. Modified cell-binding agents
• the cell-binding agent modified by reaction with crosslinkers of the present invention are preferably represented by the formula (III)
• Z is an F1-E1-P-E2-F2 unit
• Z is an F1-E1-P-E2-F2 unit
• the modified cell-binding agent can be prepared by reacting the cell-binding agent with the charged crosslinkers by methods known in the art for other crosslinkers (U.S. Patent Nos. 6,340,701 Bl, 5,846,545, 5,585,499, 5,475,092, 5,414,064, 5,208,020, and 4,563,304; R.V.J. Chari et al. Cancer Research 52, 127-131, 1992; R.V.J. Chari et al. Cancer Research 55, 4079-4084, 1995; J. Carlsson et al. 173 Biochem. J. (1978) 723-737(1978); Goff, D. A., Carroll, S. F. 1 BioConjugate Chem.
• the reaction between the cell-binding agent and the cross-linker can be conducted in aqueous solution.
• the cross- linking reagent is dissolved in aqueous buffer, optionally containing a small amount (typically ⁇ 10% by volume) of a polar organic solvent that is miscible with water, for example different alcohols, such as methanol, ethanol, and propanol, dimethyl formamide, dimethyl acetamide, or dimethylsulfoxide at a high concentration, for example 1-100 mM, and then an appropriate aliquot is added to the buffered aqueous solution of the cell-binding agent.
• a polar organic solvent that is miscible with water
• a polar organic solvent that is miscible with water
• different alcohols such as methanol, ethanol, and propanol
• dimethyl formamide dimethyl acetamide
• dimethylsulfoxide dimethylsulfoxide
• An appropriate aliquot is an amount of solution that introduces 1-10 cross-linking groups per cell-binding agent, preferably 1 -5 groups, and the volume to be added should not exceed 10 %, preferably 5 %, and most preferably 0-3 % of the volume of the cell-binding agent solution.
• the aqueous solutions for the cell -binding agents are buffered between pH 6 and 9, preferably between 6.5 and 7.5 and can contain any non-nucleophilic buffer salts useful for these pH ranges.
• Typical buffers include phosphate, triethanolamine.HCl, HEPES, and MOPS buffers, which can contain additional components, such as sucrose and salts, for example, NaCl.
• the reaction is incubated at a temperature of from 4 0 C to 40 0 C, preferably at ambient temperature.
• the progress of the reaction can be monitored by measuring the increase in the absorption at 495 nm or another appropriate wavelength.
• isolation of the modified cell-binding agent can be performed in a routine way, using for example gel filtration chromatography, or adsorptive chromatography.
• FIG. 56 shows the results from the modification of the cell-binding agent, the C242 antibody, with a sulfonate crosslinker of the present invention.
• the time course of linker/antibody (L/ A) incorporation is shown, for example, along with the drugs/antibody (D/ A) linked.
• the charged or pro-charged crosslinkers described herein have diverse functional groups that can react with any cell-binding agent that possesses a suitable substituent.
• cell-binding agents bearing an amino or hydroxyl substituent can react with crosslinkers bearing an N-hydroxysuccinimide ester
• cell-binding agents bearing a thiol substituent can react with crosslinkers bearing a maleimido or haloacetyl group
• cell-binding agents bearing a carbonyl substituent can react with crosslinkers bearing a hydrazide.
• One skilled in the art can readily determine which crosslinker to use based on the known reactivity of the available functional group on the cell-binding agent.
• Crosslinkers bearing a positive charge for example, compound
• a cell binding agent 214, Figure 71 can be directly reacted with a cell binding agent in aqueous buffer at a pH between 5 and 9, optionally containing an organic cosolvent (such as 1 to 20% dimethylaceatmide or ethanol) to provide a modified cell binding agent bearing a positive charge and a thiol group.
• the thiol group of the cell binding agent can be reacted with a cytotoxic drug bearing either a maleimido, haloacetamido or an active disulfide (example pyridyldithio, nitropyridyldithio group) to provide a conjugate.
• the conjugate can be purified by the methods described above.
• crosslinkers bearing a positive charge and a reactive ester for example, compound 216, Figure 71
• a cell binding agent for example, through its lysine amino group
• Reaction with a thiol- containing cytotoxic drug as described above can provide a conjugate bearing a positive charge.
• cytotoxic drugs modified by reaction with crosslinkers of the present invention are preferably represented by the formula (IV):
• Z is an Fl-El-P -E2-F2 unit
• Z is an F1-E1-P-E2-F2 unit
• the modified drugs can be prepared by reacting the drug with the crosslinkers of the present invention to give a modified drug of formula (IV) bearing a functionality capable of reacting with a cell binding agent.
• a thiol-containing drug can be reacted with the charged or pro- charged crosslinker of formula (I) bearing a maleimdo substituent at neutral pH in aqueous buffer to give a drug connected to the charged or pro-charged linker via a thioether link.
• a thiol-containg drug can undergo disulfide exchange with a charged or pro-charged linker bearing a pyrdiyldithio moiety to give a modified drug attached via a disulfide bond to the charged or pro- charged crosslinker.
• a drug bearing a hydroxyl group can be reacted with a charged crosslinker bearing a halogen, in the presence of a mild base, to give a modified drug bearing an ether link.
• a hydroxyl group containing drug can be condensed with a charged crosslinker of formula (I) bearing a carboxyl group, in the presence of a dehydrating agent, such as dicyclohexylcarbodimide, to give an ester link.
• An amino group containing drug can similarly undergo condensation with a carboxyl group on the charged or pro-charged crosslinker of formula (I) to give an amide bond.
• the modified drug can be purified by standard methods such as column chromatography over silica gel or alumina, crystallization, preparatory thin layer chromatography, ion exchange chromatography or HPLC.
• the cell-binding agent that comprises the conjugates and the modified cell-binding agents of the present invention may be of any kind presently known, or that become known, and includes peptides and non-peptides.
• the cell-binding agent may be any compound that can bind a cell, either in a specific or non-specific manner. Generally, these can be antibodies (especially monoclonal antibodies and antibody fragments), adnectins (US Publication No.: 20070082365), interferons, lymphokines, hormones, growth factors, vitamins, nutrient-transport molecules (such as transferrin), or any other cell-binding molecule or substance.
• the cell-binding agent is an antibody (for example, a murine, human humanized, resurfaced or a chimeric or any other antibody known to one of skill in the art), it binds to an antigen that is a polypeptide and may be a transmembrane molecule (e.g. receptor) or a ligand such as a growth factor.
• an antibody for example, a murine, human humanized, resurfaced or a chimeric or any other antibody known to one of skill in the art
• an antigen that is a polypeptide and may be a transmembrane molecule (e.g. receptor) or a ligand such as a growth factor.
• antigens include molecules such as renin; a growth hormone, including human growth hormone and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha- 1 -antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor vmc, factor IX, tissue factor (TF), and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (
• Preferred antigens for antibodies encompassed by the present invention also include CD proteins, such as CD3, CD4, CD8, CD 19, CD20, CD34, and CD46; members of the ErbB receptor family, such as the EGF receptor, HER2, HER3 or HER4 receptor; cell adhesion molecules, such as LFA-I, Macl, pl50.95, VLA-4, ICAM-I, VCAM, EpCAM, alpha 4 /beta 7 integrin, and alpha v/beta3 integrin including either alpha or beta subunits thereof (e.g.
• anti-CD 11a, anti-CD 18 or anti-CDl lb antibodies growth factors, such as VEGF; tissue factor (TF); TGF- ⁇ .; alpha interferon (alpha- IFN); an interleukin, such as IL-8; IgE; blood group antigens Apo2, death receptor; flk2/flt3 receptor; obesity (OB) receptor; mpl receptor; CTL A-4; protein C etc.
• growth factors such as VEGF; tissue factor (TF); TGF- ⁇ .; alpha interferon (alpha- IFN); an interleukin, such as IL-8; IgE; blood group antigens Apo2, death receptor; flk2/flt3 receptor; obesity (OB) receptor; mpl receptor; CTL A-4; protein C etc.
• Preferred antibodies that can be used are antibodies to CD2, CD3, CD4, CD5, CD6, CDI l, CD19, CD20, CD22, CD26, CD30, CD33, CD37, CD38, CD40, CD44, CD56, CD79, CD105, CD138, EphA receptors (e.g., EphA2 receptor), EphB receptors, EGFr, EGFRvIII, HER2, HER3, trastuzumab, pertuzumab mesothelin, cripto, integrins, VEGF, VEGFR, folate receptor (for example, FOLRl), transferrin receptor, GD3, EpCAM or an antibody which binds to one or more tumor-associated antigens or cell-surface receptors disclosed in US Publication No. 20080171040 or US Publication No. 20080305044 and are incorporated in their entirety by reference.
• EphA receptors e.g., EphA2 receptor
• EphB receptors EphB receptors
• cell-binding agents that can be used include:
• -humanized or fully human antibodies selected from but not limited to, huMy9-6, huB4, huC242, huN901, DS6, CD38, IGF-IR, CNTO 95, B-B4, trastuzumab, pertuzumab, bivatuzumab, sibrotuzumab, and rituximab (see, e.g., U.S. Patent Nos. 5,639,641, 5,665,357; and 7,342,110, U.S. Provisional Patent Application No. 60/424,332, International Patent Application WO 02/16,401, U.S. Patent Publication Number 20060045877, U.S. Patent Publication Number 20060127407, U.S.
• Additional cell-binding agents include other cell-binding proteins and polypeptides exemplified by, but not limited to:
• -interferons e.g. ⁇ , ⁇ , ⁇
• -lymphokines such as IL-2, IL-3, IL-4, IL-6;
• -hormones such as insulin, TRH (thyrotropin releasing hormones), MSH (melanocyte-stimulating hormone), steroid hormones, such as androgens and estrogens;
• -vitamins such as folic acid
• -growth factors and colony-stimulating factors such as EGF, TGF- ⁇ , G-CSF, M-CSF and GM-CSF (Burgess, Immunology Today 5:155- 158 (1984)); and
• Monoclonal antibody techniques allow for the production of specific cell-binding agents in the form of monoclonal antibodies.
• Particularly well known in the art are techniques for creating monoclonal antibodies produced by immunizing mice, rats, hamsters or any other mammal with the antigen of interest such as the intact target cell, antigens isolated from the target cell, whole virus, attenuated whole virus, and viral proteins such as viral coat proteins. Sensitized human cells can also be used.
• sFv single chain variable region
• the monoclonal antibody My9 is a murine IgG 2a antibody that is specific for the CD33 antigen found on Acute Myeloid Leukemia (AML) cells (Roy et al. Blood 77:2404-2412 (1991)) and can be used to treat AML patients.
• the monoclonal antibody anti-B4 is a murine IgGj, which binds to the CD 19 antigen on B cells (Nadler et al, J Immunol. 131:244-250 (1983)) and can be used if the target cells are B cells or diseased cells that express this antigen such as in non-Hodgkin's lymphoma or chronic lymphoblastic leukemia.
• the antibody N901 is a murine monoclonal IgGi antibody that binds to CD56 found on small cell lung carcinoma cells and on cells of other tumors of the neuroendocrine origin (Roy et al. J Nat. Cancer Inst. 88:1136-1145 (1996)), C242 antibody that binds to the CanAg antigen, pertuzumab, trastuzumab that binds to HER2/neu, and anti-EGF receptor antibody.
• GM-CSF which binds to myeloid cells
• IL-2 which binds to activated T-cells
• MSH which binds to melanocytes
• Folic acid which targets the folate receptor expressed on ovarian and other cancers is also a suitable cell-binding agent.
• Drugs that can be used in the present invention include chemotherapeutic agents.
• “Chemotherapeutic agent” is a chemical compound useful in the treatment of cancer.
• chemotherapeutic agents include alkylating agents, such as thiotepa and cyclophosphamide (CYTOXANTM); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines, such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC- 1065 (including its adozeles
• calicheamicin especially calicheamicin .gammaland calicheamicin theta I, see, e.g., Angew Chem Intl. Ed. Engl. 33:183-186 (1994); dynemicin, including dynemicin A; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromomophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin; chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L- norleucine, doxorabicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyr
• paclitaxel TAXOL ® , Bristol-Myers Squibb Oncology, Princeton, N.J.
• doxetaxel TAXOTERE ® , Rhone- Poulenc Rorer, Antony, France
• chlorambucil gemcitabine
• 6-thioguanine mercaptopurine
• methotrexate platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP- 16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-I l; topoisomerase inhibitor RFS 2000; difluoromethylomithine (DMFO); retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above.
• anti-hormonal agents that act to regulate or inhibit hormone action on tumors
• anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LYl 17018, onapristone, and toremifene (Fareston); and anti-androgens, such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; siRNA and pharmaceutically acceptable salts, acids or derivatives of any of the above.
• Other chemotherapeutic agents that can be used with the present invention are disclosed in US Publication No.
• chemotherapeutic drugs are essentially small molecule drugs.
• a "small molecule drug” is broadly used herein to refer to an organic, inorganic, or organometallic compound that may have a molecular weight of for example 100 to 1500, more suitably from 120 to 1200, favorably from 200 to 1000, and typically having a molecular weight of less than about 1000.
• Small molecule drugs of the invention encompass oligopeptides and other biomolecules having a molecular weight of less than about 1000.
• Small molecule drugs are well characterized in the art, such as in WO05058367A2, European Patent Application Nos. 85901495 and 8590319, and in U.S. Patent No. 4,956,303, among others and are incorporated in their entirety by reference.
• Preferable small molecule drugs are those that allow for linkage to the cell-binding agent.
• the invention includes known drugs as well as those that may become known.
• Especially preferred small molecule drugs include cytotoxic agents.
• the cytotoxic agent may be any compound that results in the death of a cell, or induces cell death, or in some manner decreases cell viability, wherein each cytotoxic agent comprises a thiol moiety.
• Preferred cytotoxic agents are maytansinoid compounds, taxane compounds, CC- 1065 compounds, daunorubicin compounds and doxorubicin compounds, pyrrolobenzodiazepine dimers, calicheamicins. Auristatins and analogues and derivatives thereof, some of which are described below.
• Other cytotoxic agents which are not necessarily small molecules, such as siRNA, are also encompassed within the scope of the instant invention.
• siRNAs can be linked to the crosslinkers of the present invention by methods commonly used for the modification of oligonucleotides (see, for example, US Patent Publications 20050107325 and 20070213292).
• siRNA in its 3' or 5'-phosphoromidite form is reacted with one end of the crosslinker bearing a hydroxyl functionality to give an ester bond between the siRNA and the crosslinker.
• reaction of the siRNA phosphoramidite with a crosslinker bearing a terminal amino group results in linkage of the crosslinker to the siRNA through an amine.
• siRNA are described in detail in U.S.
• Maytansinoids that can be used in the present invention are well known in the art and can be isolated from natural sources according to known methods or prepared synthetically according to known methods.
• suitable maytansinoids include maytansinol and maytansinol analogues.
• suitable maytansinol analogues include those having a modified aromatic ring and those having modifications at other positions.
• Maytansinoids with a thiol moiety at the C-3 position, the C- 14 position, the C- 15 position or the C-20 position are all expected to be useful.
• the C-3 position is preferred and the C-3 position of maytansinol is especially preferred.
• an iV-methyl-alanine-containing C-3 thiol moiety maytansinoid, and an iV-methyl-cysteine-containing C-3 thiol moiety maytansinoid, and analogues of each.
• iV-methyl-alanine-containing C-3 thiol moiety maytansinoid derivatives useful in the present invention are represented by the formulae Ml, M2, M3, M6 and M7.
• / is an integer of from 1 to 10; and may is a maytansinoid.
• R 1 and R 2 are H, CH 3 or CH 2 CH 3 , and may be the same or different; m is 0, 1, 2 or 3; and may is a maytansinoid.
• n is an integer of from 3 to 8; and may is a maytansinoid.
• M6 wherein: / is 1, 2 or 3; Y 0 is Cl or H; and X 3 is H or CH 3 .
• R 1 , R 2 , R 3 , R 4 are H, CH 3 or CH 2 CH 3 , and may be the same or different; m is O, 1, 2 or 3; and may is a maytansinoid.
• N-methyl-cysteine-containing C-3 thiol moiety maytansinoid derivatives useful in the present invention are represented by the formulae M4 and M5.
• M4 wherein: o is 1, 2 or 3; p is an integer of O to 10; and may is a maytansinoid.
• M5 wherein: o is 1, 2 or 3; q is an integer of from 0 to 10;
• Y 0 is Cl or H
• X 3 is H or CH 3 .
• Preferred maytansinoids are those described in U.S. Patent Nos. 5,208,020; 5,416,064; 6,333.410; 6,441,163; 6,716,821; RE39,151 and 7,276,497.
• the cytotoxic agent according to the present invention may also be a taxane.
• Taxanes that can be used in the present invention have been modified to contain a thiol moiety.
• Some taxanes useful in the present invention have the formula Tl shown below:
• R 1, Rj ', and R 1 " are the same or different and are H, an electron withdrawing group, such as F, NO 2 , CN, Cl, CHF 2 , or CF 3 or an electron donating group, such as -OCH 3 , -OCH 2 CH 3 , -NR 7 R 8 , -OR 9 , wherein R 7 and R 8 are the same or different and are linear, branched, or cyclic alkyl groups having 1 to 10 carbon atoms or simple or substituted aryl having 1 to 10 carbon atoms. Preferably the number of carbon atoms for R 7 and R 8 is 1 to 4. Also, preferably R 7 and R 8 are the same.
• R 8 groups include dimethyl amino, diethyl amino, dipropyl amino, and dibutyl amino, where the butyl moiety is any of primary, secondary, tertiary or isobutyl.
• R 9 is linear, branched or cyclic alkyl having 1 to 10 carbon atoms.
• R 1 preferably is OCH 3 , F, NO 2 , or CF 3 .
• R 1 is in the meta position and R 1 ' and R 1 " are
• R 2 in embodiments (1), (2) and (4) is H, heterocyclic, a linear, branched, or cyclic ester having from 1 to 10 carbon atoms or heterocyclic, a linear, branched, or cyclic ether having from 1 to 10 carbon atoms or a carbamate of the formula -CONRj 0 Rn, wherein R 10 and R 11 are the same or different and are H, linear alkyl having from 1-6 carbon atoms, branched, or cyclic alkyl having 3 to 10 atoms or simple or substituted aryl having 6 to 10 carbon atoms.
• preferred examples include -COCH 2 CH 3 and
• -COCH 2 CH 2 CH 3 preferred examples include -CH 2 CH 3 and
• R 2 in embodiment (3) is a thiol-containing moiety.
• R 3 in embodiments (1), (3) and (4), is aryl, or is linear, branched or cyclic alkyl having 1 to 10 carbon atoms, preferably
• R 4 in all four embodiments is -OC(CH 3 ) 3 or -C 6 H 5 .
• R 5 in embodiments (1) and (2) is a thiol-containing moiety
• R 6 has the same definition as above for R 2 for embodiments (1), (2) and (4).
• R 5 and R 6 in embodiment (3) are the same or different, and have the same definition as above for R 2 for embodiments (1), (2) and (4).
• R 5 in embodiment (4) has the same definition as above for R 2 for embodiments (1), (2) and (4) and R 6 is a thiol moiety.
• the preferred positions for introduction of the thiol-containing moiety are R 2 and R 5 , with R 2 being the most preferred.
• the side chain carrying the thiol moiety can be linear or branched, aromatic or heterocyclic. One of ordinary skill in the art can readily identify suitable side chains.
• thiol moieties include -(CH 2 ) n SH, -CO(CH 2 ) n SH, -(CH 2 ) n CH(CH 3 )SH, -CO(CH 2 ) n CH(CH 3 )SH, -(CH 2 ) n C(CH 3 ) 2 SH, -CO(CH 2 ) n C(CH 3 ) 2 SH, -CONR 12 (CH 2 ) n SH, -CONR 12 (CH 2 ) n CH(CH 3 )SH, or -CONRi 2 (CH 2 ) n C(CH 3 ) 2 SH, -CO- morpholino-XSH, -CO-piperazino-XSH, -CO-piperidino-XSH, and -CO-N- methylpiperazino-XSH wherein
• X is a linear alkyl or branched alkyl having 1-10 carbon atoms.
• R 12 is a linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having from 1 to 10 carbon atoms or heterocyclic, and can be H, and
• n is an integer of 0 to 10.
• linear alkyls examples include methyl, ethyl, propyl, butyl, pentyl and hexyl.
• Examples of branched alkyls include isopropyl, isobutyl, sec-butyl, tert.-butyl, isopentyl and 1-ethyl-propyl.
• Examples of cyclic alkyls include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
• Examples of simple aryls include phenyl and naphthyl.
• substituted aryls include aryls such as those described above substituted with alkyl groups, with halogens, such as Cl, Br,
• heterocyclics are compounds wherein the heteroatoms are selected from O, N, and S, and include morpholino, piperidino, piperazino, iV-methylpiperazino, pyrrollyl, pyridyl, furyl and thiophene.
• the taxanes having a thiol moiety can be synthesized according to known methods.
• the starting material for the synthesis is the commercially available 10-deacetylbaccatin III.
• the chemistry to introduce various substituents is described in several publications (Ojima et al, J Med. Chem.
• the substituent Ri on the phenyl ring and the position of the substituent Ri can be varied until a compound of the desired toxicity is obtained. Furthermore, the degree of substitution on the phenyl ring can be varied to achieve a desired toxicity. That is, the phenyl ring can have one or more substituents (e.g., mono-, di-, or tri-substitution of the phenyl ring) which provide another means for achieving a desired toxicity.
• substituents e.g., mono-, di-, or tri-substitution of the phenyl ring
• the thiol moiety can be introduced at one of the positions where a hydroxyl group already exists.
• the chemistry to protect the various hydroxyl groups, while reacting the desired one, has been described previously (see, for example, the references cited supra).
• the substituent is introduced by simply converting the free hydroxyl group to a disulfide-containing ether, a disulfide-containing ester, or a disulfide-containing carbamate. This transformation is achieved as follows.
• the desired hydroxyl group is deprotonated by treatment with the commercially-available reagent lithium hexamethyldisilazane (1.2 equivalents) in tetrahydrofuran at -4O 0 C as described in Ojima et al.
• the desired hydroxyl group can be esterified directly by reaction with an acyl halide, such as 3-bromopropionyl chloride, to give a bromo ester.
• an acyl halide such as 3-bromopropionyl chloride
• Displacement of the bromo group by treatment with potassium thioacetate and further processing as described above will provide the thiol-containing taxane ester.
• Preferred taxoids are those described in U.S. Patent Nos. 6,340,701; 6,372,738; 6.436,931; 6,596,757; 6,706,708; 7,008,942; 7,217,819 and 7,276,499.
• the cytotoxic agent according to the present invention may also be a CC- 1065 analogue.
• the CC- 1065 analogues contain an A subunit and a B or a B-C subunit.
• the A subunits are CPI (cyclopropapyrroloindole unit) in its natural closed cyclopropyl form or in its open chloromethyl form, or the closely related CBI unit (cyclopropylbenzindole unit) in the closed cyclopropyl form or the open chloromethyl form.
• the B and C subunits of CC- 1065 analogues are very similar and are 2-carboxy-indole and 2-carboxy-benzofuran derivatives.
• the analogues of CC- 1065 need at least one such 2-carboxy-indole subunit or 2-carboxy-benzofuran subunit, although two subunits (i.e., B-C) render the analogue more potent.
• two subunits i.e., B-C
• the B and C subunits can also carry different substituents at different positions on the indole or benzofuran rings.
• CC- 1065 analogues containing a thiol moiety can be any of the following A subunits of the formulae A-I ⁇ CPI (Cyclopropyl form) ⁇ , A-2 ⁇ CPI (Chloromethyl form) ⁇ , A-3 ⁇ CBI (Cyclopropyl form) ⁇ , and A-4 ⁇ CBI (Chloromethyl form) ⁇ covalently linked via an amide bond from the secondary amino group of the pyrrole moiety of the A subunit to the C-2 carboxy group of either a B subunit of the formula F-I or a B-C subunit of the formulae F-3 or F-7.
• a subunits of the formulae A-I ⁇ CPI (Cyclopropyl form) ⁇
• A-2 ⁇ CPI Chloromethyl form
• A-3 ⁇ CBI Cyclopropyl form
• A-4 ⁇ CBI (Chloromethyl form) ⁇ covalently linked via an amide bond from the secondary amino group of the pyrrole mo
• each W 1 and W 2 may be the same or different and may be O or NH; and wherein, in Formula F-I R 4 is a thiol moiety, in Formula F-3 one of R or R 4 is a thiol moiety, in Formula F-7 one of R' or R 4 is a thiol- containing moiety; when R or R' is a thiol moiety, then R 1 to R 6 , which may be the same or different, are hydrogen, C 1 -C 3 linear alkyl, methoxy, hydroxyl, primary amino, secondary amino, tertiary amino, or amido; and when R 4 is a thiol moiety, R, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 , which may be the same or different, are hydrogen, C 1 -C 3 linear alkyl, methoxy, hydroxyl, primary amino, secondary amino, tertiary amino, or amido,
• R and R' are thiol moieties and Ri and R 2 are each hydrogen. In another preferred embodiment, R and R' are thiol moieties and R 1 to R 6 are each hydrogen.
• R or R 4 is
• Examples of primary amines include methyl amine, ethyl amine and isopropyl amine.
• Examples of secondary amines include dimethyl amine, diethylamine and ethylpropyl amine.
• tertiary amines include trimethyl amine, triethyl amine, and ethyl-isopropyl-methyl amine.
• amido groups include N-methylacetamido,
• N-methyl-propionamido N-acetamido, and N-propionamido.
• alkyl represented by R' when R' is not a linking group, include C 1 -C 5 linear or branched alkyl.
• Examples of O-alkyl represented by R' when R' is not a linking group include compounds where the alkyl moiety is a C 1 -C 5 linear or branched alkyl.
• the above-described CC- 1065 analogues may be isolated from natural sources and methods for their preparation, involving subsequent modification, synthetic preparation, or a combination of both, are well- described (see, e.g., U.S. patent nos. 5,475,092, 5,585,499 and 5,846,545).
• Preferred CC-1065 analogs are those described in U.S. Patent Nos. 5,475,092; 5,595,499; 5,846,545; 6,534,660; 6,586,618; 6,756,397 and 7,049,316
• the cytotoxic agent according to the present invention may also be a daunorubicin analogue or a doxorubicin analogue.
• the daunorubicin and doxorubicin analogues of the present invention can be modified to comprise a thiol moiety.
• X is H or OH
• Y is O or NR 2 , wherein R 2 is linear or branched alkyl having 1 to 5 carbon atoms;
• R is a thiol moiety, H, or liner or branched alkyl having 1 to 5 carbon atoms;
• R' is a thiol moiety, H, or -ORi, wherein Ri is linear or branched alkyl having 1 to 5 carbon atoms; provided that R and R' are not thiol moieties at the same time.
• Ri is linear or branched alkyl having 1 to 5 carbon atoms; provided that R and R' are not thiol moieties at the same time.
• NR 2 is NCH 3 .
• R' is -O.
• the thiol moiety is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
• Examples of the linear or branched alkyl having 1 to 5 carbon atoms, represented by R, R 1 , and R 2> include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec. -butyl, tert.-butyl, and pentyl, in any of its eight isomeric arrangements.
• Ri and R 2 preferably are methyl.
• linear alkyls examples include methyl, ethyl, propyl, butyl, pentyl and hexyl.
• Examples of branched alkyls include isopropyl, isobutyl, sec-butyl, tert.-butyl, isopentyl and 1-ethyl-propyl.
• R or R' is not a linking group
• the substituent in that position can be varied until a compound of the desired toxicity is obtained.
• High toxicity is defined as having an IC 50 towards cultured cancer cells in the range of 1 x 10 ⁇ 12 to 1 x 10 "9 M, upon a 72 hour exposure time.
• substituents are H, alkyl, and O-alkyl, as described above.
• One of ordinary skill in the art can determine the appropriate chemical moiety for R and R' using only routine experimentation.
• methyl and methoxy substituents are expected to increase the cytotoxic potency, while a hydrogen is not expected to increase the potency as compared to the parent daunorubicin analogues with substituents at the different positions will be initially prepared and evaluated for in vitro cytotoxicity.
• the modified doxorubicin/daunorubicin analogues of the present invention which have a thiol moiety, are described in WO 01/38318.
• the modified doxorubicin/daunorubicin analogues can be synthesized according to known methods (see, e.g., U.S. Patent No. 5,146,064).
• Auristatin include auristatin E, auristatin EB (AEB), auristatin
• EFP EFP
• MMAE monomethyl auristatin E
• the cytotoxic agents according to the present invention include pyrrolobenzodiazepine dimers that are known in the art (US Patent Nos 7,049,311; 7.067.511; 6,951,853; 7,189,710; 6,884,799; 6,660,856.
• cytotoxic agents [170]
• cytotoxic agents described herein can be modified in such a manner that the resulting compound still retains the specificity and/or activity of the starting compound.
• the skilled artisan will also understand that many of these compounds can be used in place of the cytotoxic agents described herein.
• the cytotoxic agents of the present invention include analogues and derivatives of the compounds described herein.
• Therapeutic Use [171]
• the cell-binding agent drug conjugates (e.g., immunoconjugates) of this invention can also be used in combination with other chemotherapeutic agents. Such chemotherapeutic agents are listed above or are described in U.S. Patent No. 7,303,749.
• the cell-binding agent drug conjugates (e.g., immunoconjugates) of the present invention can be administered in vitro, in vivo and/or ex vivo to treat patients and/or to modulate the growth of selected cell populations including, for example, cancer of the lung, blood, plasma, breast, colon, prostate, kidney, pancreas, brain, bones, ovary, testes, and lymphatic organs; autoimmune diseases, such as systemic lupus, rheumatoid arthritis, and multiple sclerosis; graft rejections, such as renal transplant rejection, liver transplant rejection, lung transplant rejection, cardiac transplant rejection, and bone marrow transplant rejection; graft versus host disease; viral infections, such as CMV infection, HIV infection, and AIDS; and parasite infections, such as giardiasis, amoebiasis, schistosomiasis, and the like.
• autoimmune diseases such as systemic lupus, rheumatoid arthritis, and multiple sclerosis
• the immunoconjugates and chemotherapeutic agents of the invention are administered in vitro, in vivo and/or ex vivo to treat cancer in a patient and/or to modulate the growth of cancer cells, including, for example, cancer of the blood, plasma, lung, breast, colon, prostate, kidney, pancreas, brain, bones, ovary, testes, and lymphatic organs; more preferably lung, colon prostrate, plasma, blood or colon cancer.
• Modemating the growth of selected cell populations includes inhibiting the proliferation of selected cell populations (e.g., multiple myeloma cell populations, such as MOLP-8 cells, OPM2 cells, H929 cells, and the like) from dividing to produce more cells; reducing the rate of increase in cell division as compared, for example, to untreated cells; killing selected cell populations; and/or preventing selected cell populations (such as cancer cells) from metastasizing.
• selected cell populations e.g., multiple myeloma cell populations, such as MOLP-8 cells, OPM2 cells, H929 cells, and the like
• the growth of selected cell populations can be modulated in vitro, in vivo or ex vivo.
• the cell-binding agent drug conjugates can be administered in vitro, in vivo, or ex vivo.
• the cell-binding agent drug conjugates e.g., immunoconjugates
• suitable pharmaceutically acceptable carriers, diluents, and/or excipients which are well known, and can be determined, by one of skill in the art as the clinical situation warrants.
• Suitable carriers, diluents and/or excipients include: (1) Dulbecco's phosphate buffered saline, pH about 6.5, which would contain about 1 mg/ml to 25 mg/ml human serum albumin, (2) 0.9% saline (0.9% w/v NaCl), and (3) 5% (w/v) dextrose.
• the compounds and compositions described herein may be administered in appropriate form, preferably parenterally, more preferably intravenously.
• the compounds or compositions can be aqueous or nonaqueous sterile solutions, suspensions or emulsions.
• Propylene glycol, vegetable oils and injectable organic esters, such as ethyl oleate, can be used as the solvent or vehicle.
• the compositions can also contain adjuvants, emulsii ⁇ ers or dispersants.
• compositions can also be in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or any other injectable sterile medium.
• the "therapeutically effective amount" of the cell-binding agent drug conjugate (e.g., immunoconjugates) described herein refers to the dosage regimen for modulating the growth of selected cell populations and/or treating a patient's disease, and is selected in accordance with a variety of factors, including the age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, and pharmacological considerations, such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound used.
• the "therapeutically effective amount” can also be determined by reference to standard medical texts, such as the Physicians Desk Reference 2004.
• the patient is preferably an animal, more preferably a mammal, most preferably a human.
• the patient can be male or female, and can be an infant, child or adult.
• Examples of suitable protocols of cell-binding agent drug conjugates are as follows.
• the conjugates can be given daily for about 5 days either as an i.v., bolus each day for about 5 days, or as a continuous infusion for about 5 days.
• the conjugates can be administered once a week for six weeks or longer.
• the conjugates can be administered once every two or three weeks.
• Bolus doses are given in about 50 to about 400 ml of normal saline to which about 5 to about 10 ml of human serum albumin can be added.
• Continuous infusions are given in about 250 to about 500 ml of normal saline, to which about 25 to about 50 ml of human serum albumin can be added, per 24 hour period. Dosages will be about 10 pg to about 1000 mg/kg per person, i.v. (range of about 100 ng to about 100 mg/kg).
• kits comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compounds and/or compositions of the present invention, including, one or more immunoconjugates and one or more chemotherapeutic agents.
• kits can also include, for example, other compounds and/or compositions, a device(s) for administering the compounds and/or compositions, and written instructions in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products.
• the compounds and conjugates e.g., immunoconjugates could also be used for the manufacture of a medicament useful for treating or lessening the severity of disorders, such as, characterized by abnormal growth of cells (e.g., cancer).
• PDR Physician's Desk Reference
• the PDR discloses dosages of the agents that have been used in treatment of various cancers.
• the dosing regimen and dosages of these aforementioned chemotherapeutic agents and conjugates that are therapeutically effective will depend on the particular cancer being treated, the extent of the disease and other factors familiar to the physician of skill in the art and can be determined by the physician.
• the 2006 edition of the Physician's Desk Reference discloses that Taxotere (see p.
• Methyl 4-N-maleimido-2-suIfo-butyrate [200] In an opened round bottom flask, methyl 4-N-(3, 6-endoxo- ⁇ - tetrahydrophthalido)-2-sulfo-butyrate (0.30 g, 0.87 mmol) in 20 ml of 1:1 DMA/ 100 mM NaH 2 PO 4 , pH 7.0 was heated at 120 ⁇ 14O 0 C for 4 h. During the reaction time, 5 x 10 ml of water was gradually added to keep the reaction volume around 15 ml.
• the huC242 is modified with sulfo linker at 8 mg/mL antibody, a 15 fold molar excess of sulfo linker ( ⁇ 30mM stock solution in DMA).
• the reaction is carried out in 100 mM NaPi, pH8.0 buffer with DMA (5% v/v) for 15, 30, 120, and 200 minutes at 25 0 C.
• the modified huC242 was purified by G25 column with 50 mM NaPi, 50 mM NaCl, and 2 mM EDTA, pH6.5 to remove the excess sulfo linker.
• the molar ratio of Spy-NO 2 released per mole of huC242 antibody was calculated by measuring the A 280 of the sample and then the increase in the A 394 of the sample after adding DTT (50 ⁇ L of 1 M DTT/mL of sample).
• the concentration of DTT-released 2- mercaptopyridine is calculated using a S 394 nm of 14,205 M -1 Cm "1 .
• the concentration of antibody can then be calculated using a ⁇ 28 o n m of 217,560 M " 1 Cm "1 after subtracting the contribution of Spy-NO 2 absorbance at 280 nm (A 394 nm post DTT x 3344/14205) from the total A 280 nm measured before DTT addition.
• the molar ratio of Spy-NO 2 :Ab can then be calculated.
• the mg/mL (g/L) concentration of huC242 is calculated using a molecular weight of 147,000 g/mole.
• the modified huC242 was reacted with a 1.7-fold molar excess of DM4 (based on DM4 stock SH concentration) over Spy-NO 2 .
• the reaction is carried out at 2.5 mg/mL antibody in 50 niM NaPi, 50 mM NaCl, 2 mM EDTA, pH6.5 and DMA (5% v/v). After addition of DM4, the reaction was incubated 25 0 C for ⁇ 20 hours.
• the final conjugate was purified by G25 column with 10 mM Histidine, 130 mM Glycine, 5% sucrose, pH5.5 to remove the excess DM4 drug.
• the huC242 and DM4 both absorb at the two wavelengths used to measure each component separately, i.e., 280 and 252 nm.
• the extinction coefficient at 280 nm for huC242 is 217,560 and for DM4 is 5180 M "1 .
• the 252 nm/280 nm absorbance ratios of huC242 and DM4 are 0.368 and 5.05 respectively.
• SPP or SSNPP linker was dissolved in ethanol at a concentration of approximately 10 mM.
• Antibody was dialyzed into buffer A (50 mM KPi, 50 mM NaCl, 2 mM EDTA, pH 6.5).
• buffer A 50 mM KPi, 50 mM NaCl, 2 mM EDTA, pH 6.5.
• the linker reaction the antibody was at 8 mg/ml, and 7 equivalents of linker were added while stirring in the presence of 5% (v/v) ethanol. The reaction was allowed to proceed at ambient temperature for 90 minutes. Unreacted linker was removed from the antibody by Sephadex G25 gel filtration using a Sephadex G25 column equilibrated with Buffer A at pH 6.5 or 150 mM potassium phosphate buffer containing 100 mM NaCl, pH 7.4 as indicated.
• thiol-containing drug either DMl or DC4 was dissolved in DMA (N, iV-dimethylacetamide) at a concentration of approximately 10 mM.
• the drug (0.8 - 1.7-fold molar excess relative to the number of linker molecules per antibody as indicated) was slowly added with stirring to the antibody which was at a concentration of 2.5 mg/ml in buffer A (pH 6.5 or pH 7.4) in a final concentration of 3% (v/v) DMA.
• the reaction was allowed to proceed at ambient temperature for the indicated times.
• Drug- conjugated antibody was purified using a Sephadex G25 column equilibrated with buffer B (PBS, pH 6.5). For DML, the extent of drug conjugation to antibody was assessed by measuring A 252 and A 280 of the conjugate as described below. A similar approach was used for DC4 (see below).
• the molar ratio of pyridine-2-thione released per mole of antibody is calculated by measuring the A 280 of the sample and then the increase in the A 343 of the sample after adding DTT (50 ⁇ L of 1 M DTT/mL of sample).
• the concentration of DTT-released pyridine-2-thione is calculated using an ⁇ 343 of 8080 M -1 Cm '1 .
• the concentration of antibody can then be calculated using an ⁇ 280 of 194,712 M -1 Cm "1 after subtracting the contribution of pyridine-2-thione absorbance at 280 run (A 343 plentiful react, post DTT x 5100/8080) from the total A 280 nm measured before DTT addition.
• the molar ratio of pyridine-2-thione:Ab can then be calculated.
• the mg/mL (g/L) concentration of Ab is calculated using a molecular weight of 147,000 g/mole.
• the molar ratio of the 4-nitropyridyl-2-dithio groups linked per mole of antibody is calculated by measuring the A 280 and A 325 of the sample without DTT treatment.
• the number of antibody-bound 4-nitropyridyl-2- dithio groups is calculated using an ⁇ 325 nm of 10,964 M -1 Cm "1 .
• the concentration of antibody can then be calculated using an ⁇ 280 nm of 194,712 M -1 Cm "1 after subtracting the contribution of the 5-nitropyridyl-2-dithio group absorbance at 280 nm (A 325 nm x 3344/10964) from the total A 280 nm measured.
• the molar ratio of 4-nitropyridyl-2-dithio groups :Ab can then be calculated.
• the mg/mL (g/L) concentration of Ab is calculated using a molecular weight of 147,000 g/mole.
• the cytotoxic effects of the antibody-maytansinoid conjugates with thioether and disulfide linkers containing a sulfonate group_ were typically evaluated using a WST-8 cell-viability assay after a 4-5 day continuous incubation of the cancer cells with the conjugates.
• the antigen-expressing cancer cells (-1000-5000 cells per well) were incubated in 96-well plates in regular growth medium containing fetal bovine serum with various concentrations of the antibody-maytansinoid conjugates for about 5 days.
• the WST-8 reagent was then added and the plate absorbance was measured at 450 run after ⁇ 2-5 h.
• the survival fraction was plotted versus conjugate concentration to determine the /C 50 value (50% cell killing concentration) of the conjugate.
• Figures 60 and 61 show the enhancement in cytotoxicities of
• Anti-CanAg (huC242) - maytansinoid conjugates with the sulfonate- containing disulfide-bonded linker (huC242-Sulfo-SPDB-DM4) bearing 6.0 to 7.6 maytansinoid/ Ab compared to the conjugate with 3.3 maytansinoid/Ab toward CanAg-positive COLO205 and COLO205-MDR cells.
• the potency of the conjugates with high maytansinoids loads indicate that the decoration of the antibody with up to 8 maytansinoid molecules did not affect the conjugate binding to the target COLO205 cells.
• Figure 64 shows the cytotoxic activities of anti-CanAg Ab- maytansinoid conjugates with similar maytansinoid load against CanAg antigen-positive COLO205-MDR cells.
• the presence of sulfonate group in disulfide linker significantly enhanced conjugate potency toward these multiple drug resistant cells.
• the enhanced potency of the sulfonate-linked conjugate is a novel finding and potentially very promising for therapeutic applications.
• Figure 63 shows the cytotoxic activities of anti-EpC AM Ab- maytansinoid conjugates with similar maytansinoid load against EpCAM antigen-positive COLO205-MDR cells.
• the presence of a sulfonate group in disulfide linker significantly enhanced conjugate potency toward these multiple drug resistant cells.
• the enhanced potency of the sulfonate-linked conjugate is a novel finding and potentially very promising for therapeutic applications.
• Figure 64 shows the cytotoxic activities of anti-EpCAM Ab- maytansinoid conjugates with similar maytansinoid load against EpCAM antigen-positive HCT cells.
• the presence of a sulfonate group in the disulfide linker significantly enhanced conjugate potency toward these multiple drug resistant cells.
• the enhanced potency of the sulfonate-linked conjugate is a novel finding and potentially very promising for therapeutic applications.
• Figure 65 shows the cytotoxic activities of anti-EpCAM Ab- maytansinoid conjugates with similar maytansinoid load against EpCAM antigen-positive COLO205-MDR cells.
• the presence of a sulfonate group in the thioether linker significantly enhanced conjugate potency toward these multiple drug resistant cells.
• the enhanced potency of the sulfonate-linked conjugate is a novel finding and potentially very promising for therapeutic applications.
• Example 4 Comparison of in vivo anti-tumor activity of the anti- EpCAM-maytansinoid conjugates, B38.1-SPDB-DM4 and B38.1-sulfo- SPDB-DM4, on colon cancer, COLO205 and COLO205-MDR, xenografts:
• SPDB-DM4 conjugates was evaluated in a xenograft model of human colon carcinoma, COLO205 and COLO205-MDR, which was engineered to overexpress P-glycoprotein.
• the cells were injected subcutaneously in the area under the right shoulder of SCID mice. When the tumor's volume reached approximately 200 mm 3 in size, the mice were randomized by tumor volume and divided into three groups. Each group was treated with a single i.v. bolus of either B38.1-SPDB-DM4 (10 mg conjugate protein/kg), B38.1- sulfo-SPDB-DM4 (10 mg conjugate protein/kg) or phosphate-buffered saline (vehicle control). Tumor growth was monitored by measuring tumor size twice per week. Tumor size was calculated with the formula: length x width x height x 1 A.
• the column was eluted at 100 mL/min with deionized water containing 0.3 % formic acid and 5% acetonitrile for 10 min followed by a 13 min linear gradient from 5% acetonitrile to 33 % acetonitrile.
• Product fractions (retention time of 21 min) were combined and solvent was removed by rotary evaporation under vacuum to give 832 mg (62 %) of the title compound.
• the column was eluted at 18 mL/min with deionized water containing 0.3 % formic acid and 5% 1,4- dioxane for 3 min followed by a 15 min linear gradient from 5% 1,4-dioxane to 30 % 1,4-dioxane.
• Product fractions (retention time 6.5 min) were collected in a flask and immediately frozen in a dry ice acetone bath. Solvent was removed by lyophilization at ambient temperature to give 40 mg (42%) of the title compound.
• the column was run at 18 mL/min with deionized water containing 0.3% formic acid and 5% 1,4-dioxane for 3 min followed by an 18 min linear gradient from 5% 1,4-dioxane to 30% 1,4-dioxane.
• Product fractions (retention time 7.3 min) were collected in a flask and immediately frozen in a dry ice/acetone bath. The combined frozen material was lyophilized to give 80 mg (70 %) of the title compound.
• the purified conjugate was allowed to hold for 2d at 25 'C to allow any labile drug linkages to hydrolyze and then the conjugate was further purified from free drug by dialysis in PBS overnight, and then 10 mM histidine/130 mM glycine buffer pH 5.5 (Ix o/n).
• the dialyzed conjugate was filtered using a 0.2 um filter and assayed by UVTVis to calculate number of maytansinoids per Ab using known extinction coefficients for maytansinoid and antibody at 252 and 280 nm. The recovery was -70% and number of maytansinoids/antibody measured for each conjugate ranged from 3.7 to 6.8 depending on the linker excess used.
• Example 8 In vivo Pharmacokinetics;
• the antibody values of plasma samples were measured by ELISA (based on capture using goat-anti-hulgG antibody and detection using donkey-anti-huIgG antibody-horseradish peroxidase conjugate) and by 3 H- counting (scintillation counting).
• Figure 72 A shows that these two measurements of conjugate concentrations by ELISA and by 3 H-counting showed similar values for each conjugate.
• Both the 3.5 and 6.4 D/A Antibody-Sulfo-Mal-DM4 conjugates showed good plasma stability over 4 weeks with half-life of approximately 14.9 days and 9.7 days respectively, which are similar to the half-life of approximately 11.8 days for the unconjugated antibody.
• N901 antibody with DMl Conjugation was conducted for 2 hours at the indicated H usin a 1.7-fold molar excess of DMl er linker.
• N901 antibody with DC4 Conjugation was conducted for the indicated time at pH 7.4 using a 1.4-fold molar excess of DC4 per linker.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Epidemiology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Immunology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Crystallography & Structural Chemistry (AREA)
• Cell Biology (AREA)
• Urology & Nephrology (AREA)
• Pulmonology (AREA)
• Dermatology (AREA)
• Reproductive Health (AREA)
• Endocrinology (AREA)
• Oncology (AREA)
• Hematology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Medicinal Preparation (AREA)
• Peptides Or Proteins (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Plural Heterocyclic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (33)

Applications Claiming Priority (4)

Publications (1)

Family

ID=41255419

Family Applications (1)

Country Status (25)

Cited By (43)

Families Citing this family (165)

Citations (2)

Family Cites Families (103)

• 2009
  • 2009-04-30 KR KR1020207014337A patent/KR20200058590A/ko not_active Ceased
  • 2009-04-30 CA CA2722696A patent/CA2722696C/en active Active
  • 2009-04-30 HR HRP20171612TT patent/HRP20171612T2/hr unknown
  • 2009-04-30 KR KR1020237031373A patent/KR20230133952A/ko not_active Ceased
  • 2009-04-30 WO PCT/US2009/042267 patent/WO2009134977A1/en not_active Ceased
  • 2009-04-30 KR KR1020177021215A patent/KR101892411B1/ko not_active Expired - Fee Related
  • 2009-04-30 EP EP09739779.8A patent/EP2281006B1/en active Active
  • 2009-04-30 ES ES09739779.8T patent/ES2648122T3/es active Active
  • 2009-04-30 US US12/433,604 patent/US8236319B2/en active Active
  • 2009-04-30 NZ NZ588884A patent/NZ588884A/xx not_active IP Right Cessation
  • 2009-04-30 KR KR1020107026849A patent/KR101764927B1/ko not_active Expired - Fee Related
  • 2009-04-30 DK DK09739779.8T patent/DK2281006T3/da active
  • 2009-04-30 NO NO09739779A patent/NO2281006T3/no unknown
  • 2009-04-30 KR KR1020227007353A patent/KR20220035504A/ko not_active Ceased
  • 2009-04-30 CN CN200980125288.2A patent/CN102076717B/zh not_active Expired - Fee Related
  • 2009-04-30 PL PL09739779T patent/PL2281006T3/pl unknown
  • 2009-04-30 MY MYPI2010005030A patent/MY157165A/en unknown
  • 2009-04-30 KR KR1020217024975A patent/KR20210100223A/ko not_active Ceased
  • 2009-04-30 KR KR1020197015397A patent/KR102114915B1/ko not_active Expired - Fee Related
  • 2009-04-30 EP EP17181981.6A patent/EP3266469A3/en not_active Withdrawn
  • 2009-04-30 KR KR1020167012866A patent/KR101764081B1/ko not_active Expired - Fee Related
  • 2009-04-30 MX MX2010011807A patent/MX2010011807A/es active IP Right Grant
  • 2009-04-30 MY MYPI2021001270A patent/MY197840A/en unknown
  • 2009-04-30 PT PT97397798T patent/PT2281006T/pt unknown
  • 2009-04-30 MY MYPI2016000060A patent/MY186725A/en unknown
  • 2009-04-30 HU HUE09739779A patent/HUE034763T2/en unknown
  • 2009-04-30 KR KR1020227043110A patent/KR20230003298A/ko not_active Ceased
  • 2009-04-30 JP JP2011507634A patent/JP5769616B2/ja not_active Expired - Fee Related
  • 2009-04-30 AU AU2009243010A patent/AU2009243010B2/en not_active Ceased
  • 2009-04-30 MX MX2014002587A patent/MX347442B/es unknown
  • 2009-04-30 KR KR1020187023847A patent/KR101985885B1/ko not_active Expired - Fee Related
  • 2009-04-30 KR KR1020217000204A patent/KR20210005318A/ko not_active Withdrawn
  • 2009-04-30 CN CN201410749122.0A patent/CN104524590B/zh not_active Expired - Fee Related
  • 2009-04-30 SI SI200931755T patent/SI2281006T1/sl unknown
  • 2009-04-30 NZ NZ610239A patent/NZ610239A/en not_active IP Right Cessation
  • 2009-04-30 BR BRPI0910746A patent/BRPI0910746B8/pt not_active IP Right Cessation
  • 2009-04-30 MX MX2017000162A patent/MX359706B/es unknown
  • 2009-04-30 SG SG2013030671A patent/SG189811A1/en unknown
  • 2009-04-30 LT LTEP09739779.8T patent/LT2281006T/lt unknown
  • 2009-04-30 RU RU2010148743/04A patent/RU2503687C2/ru active
  • 2009-04-30 CN CN201410754003.4A patent/CN104524592B/zh not_active Expired - Fee Related
• 2010
  • 2010-10-26 IL IL208936A patent/IL208936B/en active IP Right Grant
• 2012
  • 2012-07-05 US US13/542,126 patent/US8613930B2/en active Active
• 2013
  • 2013-11-14 US US14/080,377 patent/US9061995B2/en active Active
• 2015
  • 2015-01-30 JP JP2015016626A patent/JP6021963B2/ja not_active Expired - Fee Related
  • 2015-05-15 US US14/713,419 patent/US9498541B2/en active Active
• 2016
  • 2016-10-04 JP JP2016196097A patent/JP6267304B2/ja not_active Expired - Fee Related
  • 2016-10-14 US US15/293,579 patent/US20170157264A1/en not_active Abandoned
• 2017
  • 2017-12-21 JP JP2017244961A patent/JP2018090587A/ja active Pending
• 2018
  • 2018-03-05 US US15/911,571 patent/US10494431B2/en active Active
  • 2018-05-18 HK HK18106522.4A patent/HK1246695A1/en unknown
• 2019
  • 2019-02-05 IL IL264672A patent/IL264672B/en active IP Right Grant
  • 2019-07-04 JP JP2019124902A patent/JP2019218350A/ja active Pending
  • 2019-10-14 US US16/601,065 patent/US11046762B2/en active Active
• 2021
  • 2021-05-13 IL IL283205A patent/IL283205A/en unknown
  • 2021-07-09 JP JP2021114005A patent/JP2021176864A/ja active Pending
• 2022
  • 2022-12-27 JP JP2022209429A patent/JP2023036868A/ja active Pending

Patent Citations (2)

Non-Patent Citations (1)